Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 6/20 | 0.74 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.74 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.74 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.74 |
| ▸ | GSK3B | P49841 | 6/20 | 0.51 |
| ▸ | CDK2 | P24941 | 4/20 | 0.51 |
| ▸ | CDK4 | P11802 | 4/20 | 0.48 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.44 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.44 |
| ▸ | CDK1 | P06493 | 2/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.44 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
| ▸ | PLK4 | O00444 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | INSR | P06213 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12897963 | 0.96 | MAPK9 (0.73) | MAPK9MAPK10PDE4BPDE10AGSK3B | |
| SCHEMBL5209413 | 0.87 | MAPK9 (0.55) | MAPK9MAPK10PDE4BPDE10AGSK3B | |
| SCHEMBL13044398 | 0.85 | MAPK9 (1.00) | MAPK9MAPK10PDE4BPDE10AGSK3B | |
| SCHEMBL5430843 | 0.83 | MAPK9 (0.59) | MAPK9MAPK10PDE4BPDE10AGSK3B | |
| SCHEMBL5432806 | 0.82 | MAPK9 (0.50) | MAPK9MAPK10PDE4BPDE10AGSK3B | |
| SCHEMBL5422622 | 0.81 | MAPK9 (0.50) | MAPK9MAPK10PDE4BPDE10AGSK3B | |
| SCHEMBL13044530 | 0.81 | PDE4B (0.59) | MAPK9MAPK10PDE4BPDE10AGSK3B | |
| SCHEMBL5426757 | 0.81 | MAPK9 (0.52) | MAPK9MAPK10PDE4BPDE10AGSK3B | |
| SCHEMBL5426190 | 0.81 | MAPK9 (0.56) | MAPK9MAPK10PDE4BPDE10AGSK3B | |
| SCHEMBL5427918 | 0.81 | MAPK9 (0.52) | MAPK9MAPK10PDE4BPDE10AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7153863-B2 | Therapeutic compounds based on pyrazolopyridline derivatives | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-26 | — | — | US | claimed |
| US-20050282842-A1 | Therapeutic compounds based on pyrazolopyridine derivatives | SMITHKLINE BEECHAM CORPORATION | 2005-12-22 | — | — | US | claimed |
| US-20110039873-A1 | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY | MEDICINOVA, INC. | 2011-02-17 | — | — | US | disclosed |
| WO-2010144416-A1 | SUBSTITUTED PYRAZOLO [1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY | GAETA FEDERICO C A (US) | 2010-12-16 | — | — | WO | disclosed |
| US-20070112014-A1 | Therapeutic Compounds Based on Pyrazolopyridine | GUDMUNDSSON KRISTJAN S | 2007-05-17 | — | — | US | disclosed |
| US-20070112014-A1 | Therapeutic Compounds Based on Pyrazolopyridine | GUDMUNDSSON KRISTJAN S | 2007-05-17 | — | — | US | disclosed |
| US-20070112014-A1 | Therapeutic Compounds Based on Pyrazolopyridine | GUDMUNDSSON KRISTJAN S | 2007-05-17 | — | — | US | disclosed |
| US-7153863-B2 | Therapeutic compounds based on pyrazolopyridline derivatives | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-26 | — | — | US | disclosed |
| US-20050282842-A1 | Therapeutic compounds based on pyrazolopyridine derivatives | SMITHKLINE BEECHAM CORPORATION | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282842-A1 | Therapeutic compounds based on pyrazolopyridine derivatives | CYP3A5, QDPR, DPYD | MAPK9 1045/4885MAPK10 2246/4885PDE4B 77/4885 |
| US-20110039873-A1 | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY | PARK7, MAPKAPK5, MAPK1 | MAPK9 65/4885MAPK10 68/4885PDE4B 43/4885 |
| US-20070112014-A1 | Therapeutic Compounds Based on Pyrazolopyridine | CYP3A5, QDPR, DPYD | MAPK9 1306/4885MAPK10 2260/4885PDE4B 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.